Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Appili Therapeutics Inc. (APLIF : OTC)
 
 • Company Description   
Appili Therapeutics Inc. is a biopharmaceutical company. It acquires, develops and commercializes novel medicines for unmet needs in the infectious disease. The company's lead product consist ATI-2307, ATI-1501 and ATI-1701 which are in clinical stage. Appili Therapeutics Inc. is based in Halifax, Canada.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.07 Daily Weekly Monthly
20 Day Moving Average: 7,397 shares
Shares Outstanding: 71.27 (millions)
Market Capitalization: $4.80 (millions)
Beta: -1.32
52 Week High: $0.90
52 Week Low: $0.06
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -24.30% -17.11%
12 Week -31.47% -22.98%
Year To Date -24.97% -8.34%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
21-1344 SUMMER ST.
-
HALIFAX,A5 B3H 0A8
CAN
ph: 902-442-4655
fax: -
None http://www.appilitherapeutics.com
 
 • General Corporate Information   
Officers
Armand Balboni - Chief Executive Officer
Ian Mortimer - Chairman
Kimberly Stephens - Chief Financial Officer
Myriam Triest - Director
Stephane Paquette - Director

Peer Information
Appili Therapeutics Inc. (CORR.)
Appili Therapeutics Inc. (RSPI)
Appili Therapeutics Inc. (CGXP)
Appili Therapeutics Inc. (BGEN)
Appili Therapeutics Inc. (GTBP)
Appili Therapeutics Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03783R107
SIC: 2834
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 06/23/22
Share - Related Items
Shares Outstanding: 71.27
Most Recent Split Date: (:1)
Beta: -1.32
Market Capitalization: $4.80 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.20 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 06/23/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 4.20
EPS Growth
vs. Year Ago Period: 20.00%
vs. Previous Quarter: 71.43%
Sales Growth
vs. Year Ago Period: 4,721.74%
vs. Previous Quarter: 27,625.00%
ROE
03/31/22 - -
12/31/21 - -793.06
09/30/21 - -361.19
ROA
03/31/22 - -
12/31/21 - -203.47
09/30/21 - -178.30
Current Ratio
03/31/22 - -
12/31/21 - 1.04
09/30/21 - 0.78
Quick Ratio
03/31/22 - -
12/31/21 - 1.04
09/30/21 - 0.78
Operating Margin
03/31/22 - -
12/31/21 - -1,874.06
09/30/21 - -40,158.18
Net Margin
03/31/22 - -
12/31/21 - -1,874.06
09/30/21 - -40,158.18
Pre-Tax Margin
03/31/22 - -
12/31/21 - -1,863.98
09/30/21 - -39,961.82
Book Value
03/31/22 - -
12/31/21 - 0.00
09/30/21 - -0.05
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©